[1] Wang CC, Cheng PN, Kao JH. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther, 2020, 51(2):216-230.
[2] Chen XL, Han YD, Wang H. Relations of hepatic steatosis with liver functions, inflammations, glucolipid metabolism in chronic hepatitis B patients. Eur Rev Med Pharmacol Sci, 2018, 22(17):5640-5646.
[3] Wu Y, Lou X. Multifocal lipoatrophy secondary to insulin injection in a patient with type 2 diabetes, hepatitis B virus infection, and liver cirrhosis. J Int Med Res, 2021, 49(3): 952-958.
[4] Uchida Y, Nakao M, Tsuji S, et al. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate. J Med Virol, 2020, 92(3):329-338.
[5] 贵强, 王福生, 成军, 等. CHB防治指南(2015年版). 中华实验和临床感染病杂志(电子版), 2015, 19(5):1-18.
[6] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版). 中国实用内科杂志, 2018, 38(4):292-344.
[7] 范小玲, 李蕴铷. 病毒性肝炎相关性糖尿病治疗专家共识. 中国肝脏病杂志(电子版), 2011, 3(2):51-55.
[8] Razi B, Alizadeh S, Omidkhoda A, et al. Association of chronic hepatitis B infection with metabolic syndrome and its components: Meta-analysis of observational studies. Diabetes Metab Syndr, 2017, 2(1):S939-S947.
[9] Xu C, Chen J, Zhang PA. Relationship Between Diabetes Mellitus and Cirrhosis Risk in Chronic Hepatitis B Patients in Wuhan, China. Med Sci Monit, 2019, 25(6):8112-8119.
[10] Li X, Xu H, Gao P. Diabetes Mellitus is a Risk Factor for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection in China. Med Sci Monit, 2018, 24(3):6729-6734.
[11] Chiang CH, Kuo CS, Lin WW, et al. Chronic Viral Hepatitis Signifies the Association of Premixed Insulin Analogues with Liver Cancer Risks: A Nationwide Population-Based Study. Int J Environ Res Public Health, 2019, 16(12):2097-2105.
[12] Peng S, Wan Z, Lin X, et al. Maternal hepatitis B surface antigen carrier status increased the incidence of gestational diabetes mellitus. BMC Infect Dis, 2019, 19(1):147-155.
[13] Han Y, Zeng A, Liao H, et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis. Int Immunopharmacol, 2017, 42(9):168-175.
[14] Hagiwara S, Nishida N, Ida H, et al. Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. J Med Virol, 2019, 91(10):1804-1810.
[15] Ogawa E, Nomura H, Nakamuta M, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int, 2020, 40(7):1578-1589.
[16] 王庆强, 钱晶晶, 左凌云, 等. 恩替卡韦治疗CHB对机体炎症反应、肝功能及肝纤维化的影响. 海南医学院学报, 2018, 24(14):22-25.
[17] 周义录, 李健. 不同降糖药物对合并乙型肝炎的2型糖尿病患者的控糖效果. 中国临床研究, 2019, 32(8):89-92.
[18] Nishimura T, Iijima H, Nishikawa H,et al. Liver fibrosis markers as assessed by ultrasound elastography and serum samples: A large comparative study in hepatitis virus B and C liver diseases. Hepatol Res, 2019, 49(7):721-730.
[19] Dong H, Xu C, Zhou W, et al. The combination of 5 serum markers compared to FibroScan to predict significant liver fibrosis in patients with chronic hepatitis B virus. Clin Chim Acta, 2018, 483(7):145-150.
[20] 申文晓, 赵永忠, 秦韬,等. CHB和乙型肝炎肝硬化患者血清高尔基体蛋白73、Ⅲ型前胶原、Ⅳ型胶原、层粘连蛋白水平及其临床意义. 广西医学, 2019(10):1227-1230.
[21] 索成云, 崔向青, 李艳芬, 等. 恩替卡韦联合心肝宝胶囊治疗CHB肝纤维化疗效观察. 现代中西医结合杂志, 2019, 28(12):1339-1342. |
